查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1675648

抗结核病治疗市场报告，按疾病类型（活动性结核病、潜伏性结核病和其他）、诊断和治疗（诊断、治疗）、最终用户（医院、专科诊所、家庭护理和其他）和地区划分，2025 年至 2033 年

Anti-Tuberculosis Therapeutics Market Report by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2024IMARC Group全球抗结核治疗市场规模达到 15.301 亿美元。医疗支出的增加、优惠的报销政策、技术进步以及不断发展的公私合作伙伴关係是推动市场发展的一些关键因素。

抗结核治疗是指用于治疗结核病（TB）的药物和治疗策略，结核病是一种由结核分枝桿菌引起的细菌感染。结核病主要影响肺部，也可扩散至身体的其他部位，如肾臟、脊椎和脑部。抗结核疗法用于消灭体内的细菌并防止感染的扩散。这是透过联合使用通常需要六至九个月的抗生素来实现的。一些最常用的药物包括异烟肼、利福平、乙胺丁醇和吡嗪酰胺。所用药物的具体组合取决于感染的严重程度和患者的健康状况。此外，定期监测和追踪对于确保治疗成功和防止抗药性结核病的发展也至关重要。近年来，抗结核治疗越来越受到关注，因为它还涉及支持性护理，例如氧气疗法、营养支持和可能出现的併发症的管理。

抗结核治疗市场趋势：

推动市场发展的主要因素之一是全球结核病（TB）的高发生率，尤其是在中低收入国家。此外，由于治疗不完善、医疗基础设施不足以及缺乏适当的医疗保健而导致的抗药性结核病发病率不断增加，对市场成长产生了积极影响。除此之外，新药和治疗策略的发展也推动了抗结核治疗市场的发展。近年来，贝达喹啉、德拉马尼等多种新药已获批准用于治疗结核病。与传统结核病药物相比，这些药物的疗效和安全性均有所提升。同时，技术和诊断技术的进步使得结核病能够早期发现和诊断，从而及时开始治疗并获得更好的患者治疗效果，这是另一个主要的成长诱导因素。此外，特别是新兴经济体的医疗支出增加，改善了医疗基础设施，增加了获得优质医疗服务的机会，包括结核病治疗。除此之外，人们对结核病的认识不断提高以及早期诊断和治疗的重要性也增加了对抗结核病治疗的需求。此外，政府对结核病控制计画的措施和资助在推动抗结核治疗市场方面发挥了重要作用。例如，政府和非政府组织 (NGO) 正在共同努力提高意识、改善诊断并确保获得负担得起且有效的治疗，预计将在未来几年推动市场成长。

本报告回答的关键问题：

  • 全球抗结核治疗市场迄今表现如何？
  • 全球抗结核治疗市场的驱动因素、限制因素和机会有哪些？
  • 每个驱动因素、限制因素和机会对全球抗结核治疗市场有何影响？
  • 主要的区域市场有哪些？
  • 哪些国家拥有最具吸引力的抗结核治疗市场？
  • 根据疾病类型，市场分布如何？
  • 抗结核病治疗市场上最具吸引力的疾病类型是哪一种？
  • 根据诊断和治疗，市场如何划分？
  • 抗结核治疗市场上最具吸引力的诊断和治疗方法是什么？
  • 根据最终用户，市场分布如何？
  • 抗结核治疗市场中最具吸引力的最终用户是谁？
  • 全球抗结核治疗市场的竞争结构是怎么样的？
  • 全球抗结核治疗市场的主要参与者/公司有哪些？

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球抗结核治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疾病类型

  • 活动性结核病
  • 潜伏性结核病
  • 其他的

第七章：市场分化：诊断与治疗

  • 诊断
    • 关键部分
      • 血液检查
      • 影像学检查
      • 痰液侦测
      • 其他的
  • 治疗
    • 关键部分
      • 一线药物
        • 主要类型
          • 异烟肼
          • 乙胺丁醇
          • 利福平
          • 其他的
      • 二线药物
        • 主要类型
          • 硫乙酰酮
          • 对氨基水杨酸 (PAS)
          • 其他的
      • 其他的

第 8 章：市场区隔：依最终用户

  • 医院
  • 专科诊所
  • 居家护理
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 10 章：驱动因素、限制因素与机会

  • 概述
  • 驱动程式
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • F. Hoffmann-La Roche Ltd.
    • Lannett Company Inc.
    • Lupin Limited
    • Macleods Pharmaceuticals Limited
    • Otsuka Pharmaceutical Co. Ltd
Product Code: SR112025A7629

The global anti-tuberculosis therapeutics market size reached USD 1,530.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,552.2 Million by 2033, exhibiting a growth rate (CAGR) of 5.56% during 2025-2033. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.

Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.

Anti-Tuberculosis Therapeutics Market Trends:

One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.

Key Market Segmentation:

Disease Type Insights:

  • Active TB
  • Latent TB
  • Others

Diagnosis and Treatment Insights:

  • Diagnosis
  • Blood Tests
  • Imaging Tests
  • Sputum Tests
  • Others
  • Treatment
  • First-Line of Drugs
  • Isoniazid
  • Ethambutol
  • Rifampin
  • Others
  • Second-Line of Drugs
  • Thiacetazone
  • Paraaminosalicyclic Acid (PAS)
  • Others
  • Others

End User Insights:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years ?
  • What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market ?
  • What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market ?
  • What are the key regional markets ?
  • Which countries represent the most attractive anti-tuberculosis therapeutics market ?
  • What is the breakup of the market based on the disease type ?
  • Which is the most attractive disease type in the anti-tuberculosis therapeutics market ?
  • What is the breakup of the market based on the diagnosis and treatment ?
  • Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market ?
  • What is the breakup of the market based on end user ?
  • Which is the most attractive end user in the anti-tuberculosis therapeutics market ?
  • What is the competitive structure of the global anti-tuberculosis therapeutics market ?
  • Who are the key players/companies in the global anti-tuberculosis therapeutics market ?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Tuberculosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Active TB
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Latent TB
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Tests
      • 7.1.2.2 Imaging Tests
      • 7.1.2.3 Sputum Tests
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 First-Line of Drugs
        • 7.2.2.1.1 Major Types
          • 7.2.2.1.1.1 Isoniazid
          • 7.2.2.1.1.2 Ethambutol
          • 7.2.2.1.1.3 Rifampin
          • 7.2.2.1.1.4 Others
      • 7.2.2.2 Second-Line of Drugs
        • 7.2.2.2.1 Major Types
          • 7.2.2.2.1.1 Thiacetazone
          • 7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
          • 7.2.2.2.1.3 Others
      • 7.2.2.3 Others
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Homecare
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 F. Hoffmann-La Roche Ltd.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Lannett Company Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Lupin Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Macleods Pharmaceuticals Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Otsuka Pharmaceutical Co. Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2024
  • Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2024
  • Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
  • Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million USD), 2025-2033
  • Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
  • Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players